Tag
Tejash Maheshchandra Hathi
3 articles
Aptus Pharma FY26 Revenue Jumps 89.7% YoY
Aptus Pharma Limited submitted its FY26 investor presentation, reporting an 89.7% YoY revenue growth to ₹46.57 crore.
PAT increased 49.0% to ₹4.62 crore, with an EBITDA of ₹7.45 crore and a margin of
Aptus Pharma FY26 Revenue Jumps 90% to ₹46.6 Crore
Aptus Pharma Limited submitted its Annual Report for FY 2025-26, reporting revenue growth of 89.65% to ₹4,657.46 lakh and PAT growth of 49.05% to ₹461.99 lakh.
The company expanded its product portfol
Aptus Pharma ₹44.88 Crore Preferential Allotment Notice
Aptus Pharma Limited announces its 16th AGM on September 14, 2026, to be held virtually via VC/OAVM.
Seeks shareholder approval for preferential allotment of 16,02,870 equity shares at ₹280 each to ra